COGNITIVE / DIRECT CATALOG PRICING
Cerebrolysin
Cerebrolysin is a named porcine-brain protein hydrolysate consisting of a mixture of low-molecular-weight peptides and amino acids, not one defined peptide. A catalog amount of 60 mg does not by itself establish equivalence to a studied commercial formulation.
- Format
- Lyophilized research vial
- Listed formats
- 1
- Available now
- 0
- Catalog class
- Cognitive
Choose a listed format
- 60 mgRequest current pricingRequest pricing
Pricing, availability, quantity tiers, and member eligibility are checked again when an order is submitted.
TECHNICAL OVERVIEW
Identity first, claims kept in scope.
Cerebrolysin is a named porcine-brain protein hydrolysate consisting of a mixture of low-molecular-weight peptides and amino acids, not one defined peptide. A catalog amount of 60 mg does not by itself establish equivalence to a studied commercial formulation.
The cognitive classification supports catalog navigation; it does not establish efficacy, safety, approval, human use, or equivalence to a material used in a cited study.
SPECIFICATIONS
- Material class
- Cognitive
- Physical format
- Lyophilized vial
- Research status
- Research purposes only
- Commerce status
- Contact for current availability
PLAIN-LANGUAGE RESEARCH SNAPSHOT
What researchers have actually studied.
Cerebrolysin is a named porcine-brain protein hydrolysate consisting of a mixture of low-molecular-weight peptides and amino acids, not one defined peptide. A catalog amount of 60 mg does not by itself establish equivalence to a studied commercial formulation.
- Research covered
- Randomized human studies have evaluated commercial Cerebrolysin formulations in neurological conditions. A 146-patient acute-stroke trial reported no significant improvement in its main neurological or functional measures, while a smaller 53-participant Alzheimer disease study reported changes in cognitive and global scales after four weeks. These studies concern a specific complex formulation, not an arbitrary peptide fraction.
- Important limit
- The formulation is heterogeneous and brand/process dependent; evidence cannot be transferred without compositional equivalence. Trial findings are condition-specific and mixed, and do not support a general cognitive claim. The catalog material needs origin, manufacturing, and analytical documentation.
FACTUAL FAQ
Cerebrolysin catalog questions
What formats are currently listed?
60 mg. Current price and stock state appear above.
What did researchers study?
Randomized human studies have evaluated commercial Cerebrolysin formulations in neurological conditions. A 146-patient acute-stroke trial reported no significant improvement in its main neurological or functional measures, while a smaller 53-participant Alzheimer disease study reported changes in cognitive and global scales after four weeks. These studies concern a specific complex formulation, not an arbitrary peptide fraction.
What is the most important evidence limit?
The formulation is heterogeneous and brand/process dependent; evidence cannot be transferred without compositional equivalence. Trial findings are condition-specific and mixed, and do not support a general cognitive claim. The catalog material needs origin, manufacturing, and analytical documentation.
How should this listing be interpreted?
It is a research-material catalog listing, not medical guidance, a dosage recommendation, a safety or efficacy claim, or evidence of regulatory approval.
Where can I review related scientific references?
Use the PSC research library to locate general and compound-related source material. Open related research references →